Search

Your search keyword '"Valk, Peter"' showing total 1,482 results
Start Over Author "Valk, Peter" Search Limiters Academic (Peer-Reviewed) Journals
1,482 results on '"Valk, Peter"'

1. Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

Author

Huls, Gerwin, Chitu, Dana A., Tick, Lidwine, Boersma, Rinske, Breems, Dimitri, Herbers, Alexandra, Klein, Saskia K., de Jonge, Suzan, Westerweel, Peter E., Cruijsen, Marjan, Hoogendoorn, Mels, Cuijpers, Marlous, Deeren, Dries, Bailly, Benjamin, Visser, Otto, van Rhenen, Anna, Posthuma, Eduard F. M., Valk, Peter J. M., Cloos, Jacqueline, Ammatuna, Emanuele, Refos, Jeannine M., Fakkert, R., Löwenberg, Bob, and Ossenkoppele, Gert J.

Published
2024
Full Text
View/download PDF

2. Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications – a HARMONY study

Author

Hernández-Sánchez, Alberto, González, Teresa, Sobas, Marta, Sträng, Eric, Castellani, Gastone, Abáigar, María, Valk, Peter J. M., Villaverde Ramiro, Ángela, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raúl, Tettero, Jesse M., Martínez-López, Joaquín, Pratcorona, Marta, Martínez Elicegui, Javier, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Döhner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernández-Rivas, Jesús María, Huntly, Brian, Ossenkoppele, Gert, Döhner, Hartmut, and Bullinger, Lars

Published
2024
Full Text
View/download PDF

4. Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients

Author

Halik, Adriane, Tilgner, Marlon, Silva, Patricia, Estrada, Natalia, Altwasser, Robert, Jahn, Ekaterina, Heuser, Michael, Hou, Hsin-An, Pratcorona, Marta, Hills, Robert K., Metzeler, Klaus H., Fenwarth, Laurene, Dolnik, Anna, Terre, Christine, Kopp, Klara, Blau, Olga, Szyska, Martin, Christen, Friederike, Krönke, Jan, Vasseur, Loïc, Löwenberg, Bob, Esteve, Jordi, Valk, Peter J. M., Duchmann, Matthieu, Chou, Wen-Chien, Linch, David C., Döhner, Hartmut, Gale, Rosemary E., Döhner, Konstanze, Bullinger, Lars, Yoshida, Kenichi, and Damm, Frederik

Published
2024
Full Text
View/download PDF

5. Integrated drug resistance and leukemic stemness gene-expression scores predict outcomes in large cohort of over 3500 AML patients from 10 trials

Author

H. Elsayed, Abdelrahman, Cao, Xueyuan, Marrero, Richard J., Nguyen, Nam H. K., Wu, Huiyun, Ni, Yonhui, Ribeiro, Raul C., Tobias, Herold, Valk, Peter J., Béliveau, François, Richard-Carpentier, Guillaume, Hébert, Josée, Zwaan, C. Michel, Gamis, Alan, Kolb, Edward Anders, Aplenc, Richard, Alonzo, Todd A., Meshinchi, Soheil, Rubnitz, Jeffrey, Pounds, Stanley, and Lamba, Jatinder K.

Published
2024
Full Text
View/download PDF

6. Prognostic impact of CEBPA mutational subgroups in adult AML

Author

Georgi, Julia-Annabell, Stasik, Sebastian, Kramer, Michael, Meggendorfer, Manja, Röllig, Christoph, Haferlach, Torsten, Valk, Peter, Linch, David, Herold, Tobias, Duployez, Nicolas, Taube, Franziska, Middeke, Jan Moritz, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Muller-Tidow, Carsten, Haferlach, Claudia, Koch, Sarah, Berdel, Wolfgang E., Woermann, Bernhard J., Krug, Utz, Braess, Jan, Hiddemann, Wolfgang, Spiekermann, Karsten, Boertjes, Emma L., Hills, Robert K., Burnett, Alan, Ehninger, Gerhard, Metzeler, Klaus, Rothenberg-Thurley, Maja, Dufour, Annika, Dombret, Hervé, Pautas, Cecile, Preudhomme, Claude, Fenwarth, Laurene, Bornhäuser, Martin, Gale, Rosemary, and Thiede, Christian

Published
2024
Full Text
View/download PDF

7. Clinical networking results in continuous improvement of the outcome of patients with acute promyelocytic leukemia

Author

Koury, Luísa Corrêa de Araújo, Kim, Haesook T., Undurraga, Maria Soledad, Navarro-Cabrera, Juan Ramon, Salinas, Victor, Muxi, Pablo, Melo, Raul A. M., Glória, Ana Beatriz, Pagnano, Katia, Nunes, Elenaide C., Bittencourt, Rosane I., Rojas, Ninoska, Quintana, Shirley, Ayala-Lugo, Ana, Oliver, Ana Carolina, Figueiredo-Pontes, Lorena, Traina, Fabiola, Moreira, Frederico, Fagundes, Evandro M., Duarte, Bruno K. L., Mora-Alferez, Analí Pamela, Ortiz, Percy, Untama, Jose, Tallman, Martin, Ribeiro, Raul, Ganser, Arnold, Dillon, Richard, Valk, Peter J. M., Sanz, Miguel, Löwenberg, Bob, Berliner, Nancy, and Rego, Eduardo M.

Published
2024
Full Text
View/download PDF

8. STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia

Author

Fischer, Alexander, Hernández-Rodríguez, Benjamín, Mulet-Lazaro, Roger, Nuetzel, Margit, Hölzl, Fabian, van Herk, Stanley, Kavelaars, François G., Stanewsky, Hanna, Ackermann, Ute, Niang, Amadou H., Diaz, Noelia, Reuschel, Edith, Strieder, Nicholas, Hernández-López, Inmaculada, Valk, Peter J.M., Vaquerizas, Juan M., Rehli, Michael, Delwel, Ruud, and Gebhard, Claudia

Published
2024
Full Text
View/download PDF

9. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

Author

Hilberink, Jacobien R., van Zeventer, Isabelle A., Chitu, Dana A., Pabst, Thomas, Klein, Saskia K., Stussi, Georg, Griskevicius, Laimonas, Valk, Peter J. M., Cloos, Jacqueline, van de Loosdrecht, Arjan A., Breems, Dimitri, van Lammeren-Venema, Danielle, Boersma, Rinske, Jongen-Lavrencic, Mojca, Fehr, Martin, Hoogendoorn, Mels, Manz, Markus G., Söhne, Maaike, van Marwijk Kooy, Rien, Deeren, Dries, van der Poel, Marjolein W. M., Legdeur, Marie Cecile, Tick, Lidwine, Chalandon, Yves, Ammatuna, Emanuele, Blum, Sabine, Löwenberg, Bob, Ossenkoppele, Gert J., and Huls, Gerwin

Published
2023
Full Text
View/download PDF

11. Figure S10 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Author

Martin, Michael V., primary, Aguilar-Rosas, Salvador, primary, Franke, Katka, primary, Pieterse, Mark, primary, Langelaar, Jamie van, primary, Schreurs, Renée, primary, Bijlsma, Maarten F., primary, Besselink, Marc G., primary, Koster, Jan, primary, Timens, Wim, primary, Khasraw, Mustafa, primary, Ashley, David M., primary, Keir, Stephen T., primary, Ottensmeier, Christian H., primary, King, Emma V., primary, Verheij, Joanne, primary, Waasdorp, Cynthia, primary, Valk, Peter J.M., primary, Engels, Sem A.G., primary, Oostenbach, Ellen, primary, van Dinter, Jip T., primary, Hofman, Damon A., primary, Mok, Juk Yee, primary, van Esch, Wim J.E., primary, Wilmink, Hanneke, primary, Monkhorst, Kim, primary, Verheul, Henk M.W., primary, Poel, Dennis, primary, Hiltermann, T. Jeroen N., primary, Kempen, Léon C.L.T. van, primary, Groen, Harry J.M., primary, Aerts, Joachim G.J.V., primary, Heesch, Sebastiaan van, primary, Löwenberg, Bob, primary, Plasterk, Ronald, primary, and Kloosterman, Wigard P., primary

Published
2024
Full Text
View/download PDF

12. Data from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Author

Martin, Michael V., primary, Aguilar-Rosas, Salvador, primary, Franke, Katka, primary, Pieterse, Mark, primary, Langelaar, Jamie van, primary, Schreurs, Renée, primary, Bijlsma, Maarten F., primary, Besselink, Marc G., primary, Koster, Jan, primary, Timens, Wim, primary, Khasraw, Mustafa, primary, Ashley, David M., primary, Keir, Stephen T., primary, Ottensmeier, Christian H., primary, King, Emma V., primary, Verheij, Joanne, primary, Waasdorp, Cynthia, primary, Valk, Peter J.M., primary, Engels, Sem A.G., primary, Oostenbach, Ellen, primary, van Dinter, Jip T., primary, Hofman, Damon A., primary, Mok, Juk Yee, primary, van Esch, Wim J.E., primary, Wilmink, Hanneke, primary, Monkhorst, Kim, primary, Verheul, Henk M.W., primary, Poel, Dennis, primary, Hiltermann, T. Jeroen N., primary, Kempen, Léon C.L.T. van, primary, Groen, Harry J.M., primary, Aerts, Joachim G.J.V., primary, Heesch, Sebastiaan van, primary, Löwenberg, Bob, primary, Plasterk, Ronald, primary, and Kloosterman, Wigard P., primary

Published
2024
Full Text
View/download PDF

13. Supplementary Tables S1-S12 from The Neo-Open Reading Frame Peptides That Comprise the Tumor Framome Are a Rich Source of Neoantigens for Cancer Immunotherapy

Author

Martin, Michael V., primary, Aguilar-Rosas, Salvador, primary, Franke, Katka, primary, Pieterse, Mark, primary, Langelaar, Jamie van, primary, Schreurs, Renée, primary, Bijlsma, Maarten F., primary, Besselink, Marc G., primary, Koster, Jan, primary, Timens, Wim, primary, Khasraw, Mustafa, primary, Ashley, David M., primary, Keir, Stephen T., primary, Ottensmeier, Christian H., primary, King, Emma V., primary, Verheij, Joanne, primary, Waasdorp, Cynthia, primary, Valk, Peter J.M., primary, Engels, Sem A.G., primary, Oostenbach, Ellen, primary, van Dinter, Jip T., primary, Hofman, Damon A., primary, Mok, Juk Yee, primary, van Esch, Wim J.E., primary, Wilmink, Hanneke, primary, Monkhorst, Kim, primary, Verheul, Henk M.W., primary, Poel, Dennis, primary, Hiltermann, T. Jeroen N., primary, Kempen, Léon C.L.T. van, primary, Groen, Harry J.M., primary, Aerts, Joachim G.J.V., primary, Heesch, Sebastiaan van, primary, Löwenberg, Bob, primary, Plasterk, Ronald, primary, and Kloosterman, Wigard P., primary

Published
2024
Full Text
View/download PDF

15. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Author

Grob, Tim, Al Hinai, Adil S.A., Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, and Valk, Peter J.M.

Published
2022
Full Text
View/download PDF

16. Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients.

Author

Kockerols, Camille, Valk, Peter J. M., Janssen, Jeroen J. W. M., Hogenbirk, Pauline, Cornelissen, Jan J., Saussele, Susanne, Spiess, Birgit, Perusini, Maria Agustina, Kim, Dennis, and Westerweel, Peter E.

Subjects
*CHRONIC myeloid leukemia, *PROTEIN-tyrosine kinase inhibitors, *IMATINIB, *TREATMENT duration, *PROBABILITY theory
Abstract

Precise and reliable predictive parameters to accurately identify chronic myeloid leukemia (CML) patients who can successfully discontinue their tyrosine kinase inhibitor (TKI) treatment are lacking. One promising parameter is depth of molecular response measured by BCR::ABL1 digital PCR (dPCR). The aim of this study was to validate a previously described prediction cutoff of 0.0023%IS and to assess the value of dPCR for treatment‐free remission (TFR) prediction in relation to other clinical parameters. A droplet‐based dPCR assay assessed BCR::ABL1 %IS prior to TKI discontinuation. The primary endpoint was molecular recurrence (MolR) by 36 months. A total of 186 patients from Canada, Germany, and the Netherlands were included. In patients with a first TKI discontinuation attempt (n = 163), a BCR::ABL1 dPCR < and ≥0.0023%IS had a MolR probability of 33% and 70%, respectively. Patients treated less than 6 years with a BCR::ABL1 dPCR <0.0023%IS had a MolR probability of 31%. After correction for treatment duration, both high dPCR value and the use of imatinib (vs. second‐generation TKI) were significantly associated with a higher risk of MolR (HR of 3.66, 95%CI 2.06–6.51, p <.001; and 2.85, 95%CI 1.25–6.46, p =.013, respectively). BCR::ABL1 dPCR was not associated with TFR outcome after second TKI discontinuation, however, with the limitation of a small number of patients analyzed (n = 23). In conclusion, BCR::ABL1 digital PCR based on the cutoff of 0.0023%IS is a valuable predictive tool to identify CML patients with a high probability of TFR success after first TKI discontinuation, including patients treated for less than 6 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Author

Taube, Franziska, Georgi, Julia Annabell, Kramer, Michael, Stasik, Sebastian, Middeke, Jan Moritz, Röllig, Christoph, Krug, Utz, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Brümmendorf, Tim H., Naumann, Ralph, Petzold, Andreas, Mulet-Lazaro, Roger, Valk, Peter J.M., Steffen, Björn, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann, Christoph, Krause, Stefan W., Hänel, Mathias, Noppeney, Richard, Kaiser, Ulrich, Baldus, Claudia D., Kaufmann, Martin, Herold, Sylvia, Stölzel, Friedrich, Sockel, Katja, von Bonin, Malte, Müller-Tidow, Carsten, Platzbecker, Uwe, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Bornhäuser, Martin, Schetelig, Johannes, and Thiede, Christian

Published
2022
Full Text
View/download PDF

19. BCR::ABL1 digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis

Author

Kockerols, Camille, primary, Valk, Peter J. M., additional, Dulucq, Stéphanie, additional, Nicolini, Franck‐Emmanuel, additional, Mahon, François‐Xavier, additional, Atallah, Ehab, additional, Mauro, Michael J., additional, Radich, Jerald P., additional, Bernardi, Simona, additional, Russo, Domenico, additional, Farina, Mirko, additional, Mori, Silvia, additional, Gambacorti‐Passerini, Carlo, additional, Civettini, Ivan, additional, Lu, Liu, additional, Yeung, David, additional, Branford, Susan, additional, Colafigli, Gioia, additional, Breccia, Massimo, additional, Hogenbirk, Pauline, additional, van Rosmalen, Joost, additional, Cornelissen, Jan J., additional, and Westerweel, Peter E., additional

Published
2024
Full Text
View/download PDF

20. A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction

Author

Ortiz Rojas, Cesar Alexander, primary, Pereira‐Martins, Diego Antonio, additional, Bellido More, Candy Christie, additional, Sternadt, Dominique, additional, Weinhäuser, Isabel, additional, Hilberink, Jacobien R., additional, Coelho‐Silva, Juan Luiz, additional, Thomé, Carolina Hassibe, additional, Ferreira, Germano Aguiar, additional, Ammatuna, Emanuele, additional, Huls, Gerwin, additional, Valk, Peter J., additional, Schuringa, Jan Jacob, additional, and Rego, Eduardo Magalhães, additional

Published
2024
Full Text
View/download PDF

22. Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia

Author

Rapaport, Franck, Neelamraju, Yaseswini, Baslan, Timour, Hassane, Duane, Gruszczynska, Agata, Robert de Massy, Marc, Farnoud, Noushin, Haddox, Samuel, Lee, Tak, Medina-Martinez, Juan, Sheridan, Caroline, Thurmond, Alexis, Becker, Michael, Bekiranov, Stefan, Carroll, Martin, Moses Murdock, Heardly, Valk, Peter J. M., Bullinger, Lars, D’Andrea, Richard, Lowe, Scott W., Neuberg, Donna, Levine, Ross L., Melnick, Ari, and Garrett-Bakelman, Francine E.

Published
2021
Full Text
View/download PDF

25. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Author

Löwenberg, Bob, Pabst, Thomas, Maertens, Johan, Gradowska, Patrycja, Biemond, Bart J., Spertini, Olivier, Vellenga, Edo, Griskevicius, Laimonas, Tick, Lidwine W., Jongen-Lavrencic, Mojca, van Marwijk Kooy, Marinus, Vekemans, Marie-Christiane, van der Velden, Walter J.F.M., Beverloo, Berna, Michaux, Lucienne, Graux, Carlos, Deeren, Dries, de Weerdt, Okke, van Esser, Joost W.J., Bargetzi, Mario, Klein, Saskia K., Gadisseur, Alain, Westerweel, Peter E., Veelken, Hendrik, Gregor, Michael, Silzle, Tobias, van Lammeren-Venema, Daniëlle, Moors, Ine, Breems, Dimitri A., Hoogendoorn, Mels, Legdeur, Marie-Cecile J.C., Fischer, Thomas, Kuball, Juergen, Cornelissen, Jan, Porkka, Kimmo, Juliusson, Gunnar, Meyer, Peter, Höglund, Martin, Gjertsen, Bjorn T., Janssen, Jeroen J.W.M., Huls, Gerwin, Passweg, Jakob, Cloos, Jacqueline, Valk, Peter J.M., van Elssen, Catharina H.M.J., Manz, Markus G., Floisand, Yngvar, and Ossenkoppele, Gert J.

Published
2021
Full Text
View/download PDF

26. Rearrangements involving 11q23.3/KMT2A in adult AML:mutational landscape and prognostic implications - a HARMONY study

Author

Hernandez-Sanchez, Alberto, Gonzalez, Teresa, Sobas, Marta, Straeng, Eric, Castellani, Gastone, Abaigar, Maria, Valk, Peter J. M., Ramiro, Angela Villaverde, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raul, Tettero, Jesse M., Martinez-Lopez, Joaquin, Pratcorona, Marta, Elicegui, Javier Martinez, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Doehner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernandez-Rivas, Jesus Maria, Huntly, Brian, Ossenkoppele, Gert, Doehner, Hartmut, Bullinger, Lars, Hernandez-Sanchez, Alberto, Gonzalez, Teresa, Sobas, Marta, Straeng, Eric, Castellani, Gastone, Abaigar, Maria, Valk, Peter J. M., Ramiro, Angela Villaverde, Benner, Axel, Metzeler, Klaus H., Azibeiro, Raul, Tettero, Jesse M., Martinez-Lopez, Joaquin, Pratcorona, Marta, Elicegui, Javier Martinez, Mills, Ken I., Thiede, Christian, Sanz, Guillermo, Doehner, Konstanze, Heuser, Michael, Haferlach, Torsten, Turki, Amin T., Reinhardt, Dirk, Schulze-Rath, Renate, Barbus, Martje, Hernandez-Rivas, Jesus Maria, Huntly, Brian, Ossenkoppele, Gert, Doehner, Hartmut, and Bullinger, Lars

Abstract

Balanced rearrangements involving the KMT2A gene (KMT2Ar) are recurrent genetic abnormalities in acute myeloid leukemia (AML), but there is lack of consensus regarding the prognostic impact of different fusion partners. Moreover, prognostic implications of gene mutations co-occurring with KMT2Ar are not established. From the HARMONY AML database 205 KMT2Ar adult patients were selected, 185 of whom had mutational information by a panel-based next-generation sequencing analysis. Overall survival (OS) was similar across the different translocations, including t(9;11)(p21.3;q23.3)/KMT2A::MLLT3 (p = 0.756). However, independent prognostic factors for OS in intensively treated patients were age >60 years (HR 2.1, p = 0.001), secondary AML (HR 2.2, p = 0.043), DNMT3A-mut (HR 2.1, p = 0.047) and KRAS-mut (HR 2.0, p = 0.005). In the subset of patients with de novo AML < 60 years, KRAS and TP53 were the prognostically most relevant mutated genes, as patients with a mutation of any of those two genes had a lower complete remission rate (50% vs 86%, p < 0.001) and inferior OS (median 7 vs 30 months, p < 0.001). Allogeneic hematopoietic stem cell transplantation in first complete remission was able to improve OS (p = 0.003). Our study highlights the importance of the mutational patterns in adult KMT2Ar AML and provides new insights into more accurate prognostic stratification of these patients. (Figure presented.).

Published
2024

29. Genomic characterization of AML with aberrations of chromosome 7:a multinational cohort of 519 patients

Author

Halik, Adriane, Tilgner, Marlon, Silva, Patricia, Estrada, Natalia, Altwasser, Robert, Jahn, Ekaterina, Heuser, Michael, Hou, Hsin An, Pratcorona, Marta, Hills, Robert K., Metzeler, Klaus H., Fenwarth, Laurene, Dolnik, Anna, Terre, Christine, Kopp, Klara, Blau, Olga, Szyska, Martin, Christen, Friederike, Krönke, Jan, Vasseur, Loïc, Löwenberg, Bob, Esteve, Jordi, Valk, Peter J.M., Duchmann, Matthieu, Chou, Wen Chien, Linch, David C., Döhner, Hartmut, Gale, Rosemary E., Döhner, Konstanze, Bullinger, Lars, Yoshida, Kenichi, Damm, Frederik, Halik, Adriane, Tilgner, Marlon, Silva, Patricia, Estrada, Natalia, Altwasser, Robert, Jahn, Ekaterina, Heuser, Michael, Hou, Hsin An, Pratcorona, Marta, Hills, Robert K., Metzeler, Klaus H., Fenwarth, Laurene, Dolnik, Anna, Terre, Christine, Kopp, Klara, Blau, Olga, Szyska, Martin, Christen, Friederike, Krönke, Jan, Vasseur, Loïc, Löwenberg, Bob, Esteve, Jordi, Valk, Peter J.M., Duchmann, Matthieu, Chou, Wen Chien, Linch, David C., Döhner, Hartmut, Gale, Rosemary E., Döhner, Konstanze, Bullinger, Lars, Yoshida, Kenichi, and Damm, Frederik

Abstract

Background: Deletions and partial losses of chromosome 7 (chr7) are frequent in acute myeloid leukemia (AML) and are linked to dismal outcome. However, the genomic landscape and prognostic impact of concomitant genetic aberrations remain incompletely understood. Methods: To discover genetic lesions in adult AML patients with aberrations of chromosome 7 [abn(7)], 60 paired diagnostic/remission samples were investigated by whole-exome sequencing in the exploration cohort. Subsequently, a gene panel including 66 genes and a SNP backbone for copy-number variation detection was designed and applied to the remaining samples of the validation cohort. In total, 519 patients were investigated, of which 415 received intensive induction treatment, typically containing a combination of cytarabine and anthracyclines. Results: In the exploration cohort, the most frequently mutated gene was TP53 (33%), followed by epigenetic regulators (DNMT3A, KMT2C, IDH2) and signaling genes (NRAS, PTPN11). Thirty percent of 519 patients harbored ≥ 1 mutation in genes located in commonly deleted regions of chr7—most frequently affecting KMT2C (16%) and EZH2 (10%). KMT2C mutations were often subclonal and enriched in patients with del(7q), de novo or core-binding factor AML (45%). Cancer cell fraction analysis and reconstruction of mutation acquisition identified TP53 mutations as mainly disease-initiating events, while del(7q) or −7 appeared as subclonal events in one-third of cases. Multivariable analysis identified five genetic lesions with significant prognostic impact in intensively treated AML patients with abn(7). Mutations in TP53 and PTPN11 (11%) showed the strongest association with worse overall survival (OS, TP53: hazard ratio [HR], 2.53 [95% CI 1.66–3.86]; P < 0.001; PTPN11: HR, 2.24 [95% CI 1.56–3.22]; P < 0.001) and relapse-free survival (RFS, TP53: HR, 2.3 [95% CI 1.25–4.26]; P = 0.008; PTPN11: HR, 2.32 [95% CI 1.33–

Published
2024

30. Prognostic impact of CEBPA mutational subgroups in adult AML

Author

Georgi, Julia Annabell, Stasik, Sebastian, Kramer, Michael, Meggendorfer, Manja, Röllig, Christoph, Haferlach, Torsten, Valk, Peter, Linch, David, Herold, Tobias, Duployez, Nicolas, Taube, Franziska, Middeke, Jan Moritz, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Muller-Tidow, Carsten, Haferlach, Claudia, Koch, Sarah, Berdel, Wolfgang E., Woermann, Bernhard J., Krug, Utz, Braess, Jan, Hiddemann, Wolfgang, Spiekermann, Karsten, Boertjes, Emma L., Hills, Robert K., Burnett, Alan, Ehninger, Gerhard, Metzeler, Klaus, Rothenberg-Thurley, Maja, Dufour, Annika, Dombret, Hervé, Pautas, Cecile, Preudhomme, Claude, Fenwarth, Laurene, Bornhäuser, Martin, Gale, Rosemary, Thiede, Christian, Georgi, Julia Annabell, Stasik, Sebastian, Kramer, Michael, Meggendorfer, Manja, Röllig, Christoph, Haferlach, Torsten, Valk, Peter, Linch, David, Herold, Tobias, Duployez, Nicolas, Taube, Franziska, Middeke, Jan Moritz, Platzbecker, Uwe, Serve, Hubert, Baldus, Claudia D., Muller-Tidow, Carsten, Haferlach, Claudia, Koch, Sarah, Berdel, Wolfgang E., Woermann, Bernhard J., Krug, Utz, Braess, Jan, Hiddemann, Wolfgang, Spiekermann, Karsten, Boertjes, Emma L., Hills, Robert K., Burnett, Alan, Ehninger, Gerhard, Metzeler, Klaus, Rothenberg-Thurley, Maja, Dufour, Annika, Dombret, Hervé, Pautas, Cecile, Preudhomme, Claude, Fenwarth, Laurene, Bornhäuser, Martin, Gale, Rosemary, and Thiede, Christian

Abstract

Despite recent refinements in the diagnostic and prognostic assessment of CEBPA mutations in AML, several questions remain open, i.e. implications of different types of basic region leucin zipper (bZIP) mutations, the role of co-mutations and the allelic state. Using pooled primary data analysis on 1010 CEBPA-mutant adult AML patients, a comparison was performed taking into account the type of mutation (bZIP: either typical in-frame insertion/deletion (InDel) mutations (bZIP InDel), frameshift InDel or nonsense mutations inducing translational stop (bZIP STOP) or single base-pair missense alterations (bZIP ms), and transcription activation domain (TAD) mutations) and the allelic state (single (smCEBPA) vs. double mutant (dmCEBPA)). Only bZIP InDel patients had significantly higher rates of complete remission and longer relapse free and overall survival (OS) compared with all other CEBPA-mutant subgroups. Moreover, co-mutations in bZIP InDel patients (e.g. GATA2, FLT3, WT1 as well as ELN2022 adverse risk aberrations) had no independent impact on OS, whereas in non-bZIP InDel patients, grouping according to ELN2022 recommendations added significant prognostic information. In conclusion, these results demonstrate bZIP InDel mutations to be the major independent determinant of outcome in CEBPA-mutant AML, thereby refining current classifications according to WHO (including all dmCEBPA and smCEBPA bZIP) as well as ELN2022 and ICC recommendations (including CEBPA bZIP ms). (Figure presented.)

Published
2024

32. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Author

Vadakekolathu, Jayakumar, Lai, Catherine, Reeder, Stephen, Church, Sarah E., Hood, Tressa, Lourdusamy, Anbarasu, Rettig, Michael P., Aldoss, Ibrahim, Advani, Anjali S., Godwin, John, Wieduwilt, Matthew J., Arellano, Martha, Muth, John, Yau, Tung On, Ravandi, Farhad, Sweet, Kendra, Altmann, Heidi, Foulds, Gemma A., Stölzel, Friedrich, Middeke, Jan Moritz, Ciciarello, Marilena, Curti, Antonio, Valk, Peter J.M., Löwenberg, Bob, Gojo, Ivana, Bornhäuser, Martin, DiPersio, John F., Davidson-Moncada, Jan K., and Rutella, Sergio

Published
2020
Full Text
View/download PDF

33. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing

Author

Arindrarto, Wibowo, Borràs, Daniel M., de Groen, Ruben A. L., van den Berg, Redmar R., Locher, Irene J., van Diessen, Saskia A. M. E., van der Holst, Rosalie, van der Meijden, Edith D., Honders, M. Willy, de Leeuw, Rick H., Verlaat, Wina, Jedema, Inge, Kroes, Wilma G. M., Knijnenburg, Jeroen, van Wezel, Tom, Vermaat, Joost S. P., Valk, Peter J. M., Janssen, Bart, de Knijff, Peter, van Bergen, Cornelis A. M., van den Akker, Erik B., Hoen, Peter A. C. ’t, Kiełbasa, Szymon M., Laros, Jeroen F. J., Griffioen, Marieke, and Veelken, Hendrik

Published
2021
Full Text
View/download PDF

36. The neuropeptide receptor calcitonin receptor-like (CALCRL) is a potential therapeutic target in acute myeloid leukemia

Author

Angenendt, Linus, Bormann, Eike, Pabst, Caroline, Alla, Vijay, Görlich, Dennis, Braun, Leonie, Dohlich, Kim, Schwöppe, Christian, Bohlander, Stefan K., Arteaga, Maria Francisca, Wethmar, Klaus, Hartmann, Wolfgang, Angenendt, Adrian, Kessler, Torsten, Mesters, Rolf M., Stelljes, Matthias, Rothenberg-Thurley, Maja, Spiekermann, Karsten, Hébert, Josée, Sauvageau, Guy, Valk, Peter J. M., Löwenberg, Bob, Serve, Hubert, Müller-Tidow, Carsten, Lenz, Georg, Wörmann, Bernhard J., Sauerland, M. Christina, Hiddemann, Wolfgang, Berdel, Wolfgang E., Krug, Utz, Metzeler, Klaus H., Mikesch, Jan-Henrik, Herold, Tobias, and Schliemann, Christoph

Published
2019
Full Text
View/download PDF

38. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations

Author

Jutzi, Jonas Samuel, Basu, Titiksha, Pellmann, Maximilian, Kaiser, Sandra, Steinemann, Doris, Sanders, Mathijs A., Hinai, Adil S.A., Zeilemaker, Annelieke, Bojtine Kovacs, Sarolta, Koellerer, Christoph, Ostendorp, Jenny, Aumann, Konrad, Wang, Wei, Raffoux, Emmanuel, Cassinat, Bruno, Bullinger, Lars, Schlegelberger, Brigitte, Valk, Peter J.M., and Pahl, Heike Luise

Published
2019
Full Text
View/download PDF

39. Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients

Author

Christen, Friederike, Hoyer, Kaja, Yoshida, Kenichi, Hou, Hsin-An, Waldhueter, Nils, Heuser, Michael, Hills, Robert K., Chan, Willy, Hablesreiter, Raphael, Blau, Olga, Ochi, Yotaro, Klement, Piroska, Chou, Wen-Chien, Blau, Igor-Wolfgang, Tang, Jih-Luh, Zemojtel, Tomasz, Shiraishi, Yuichi, Shiozawa, Yusuke, Thol, Felicitas, Ganser, Arnold, Löwenberg, Bob, Linch, David C., Bullinger, Lars, Valk, Peter J.M., Tien, Hwei-Fang, Gale, Rosemary E., Ogawa, Seishi, and Damm, Frederik

Published
2019
Full Text
View/download PDF

40. The neuronal homeobox transcription factor HMX3 is a crucial vulnerability factor in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia

Author

Arza-Apalategi, Saioa, primary, Heuts, Branco M. H., additional, Bergevoet, Saskia M., additional, Meering, Roos, additional, Gilissen, Daan, additional, Jansen, Pascal W. T. C., additional, Krippner-Heidenreich, Anja, additional, Valk, Peter J. M., additional, Vermeulen, Michiel, additional, Heidenreich, Olaf, additional, Haferlach, Torsten, additional, Jansen, Joop H., additional, Martens, Joost H. A., additional, and van der Reijden, Bert A., additional

Published
2023
Full Text
View/download PDF

42. BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population

Author

Kockerols, Camille, primary, Valk, Peter J. M., additional, Blijlevens, Nicole M. A., additional, Cornelissen, Jan J., additional, Dinmohamed, Avinash G., additional, Geelen, Inge, additional, Hoogendoorn, Mels, additional, Janssen, Jeroen J. W. M., additional, Daenen, Laura G. M., additional, Reijden, Bert A. van der, additional, and Westerweel, Peter E., additional

Published
2023
Full Text
View/download PDF

43. High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL

Author

Hengeveld, Paul J., primary, Kolijn, P. Martijn, additional, Demmers, Jeroen A.A., additional, Doff, Wouter, additional, Dubois, Julie M.N., additional, Rijken, Melissa, additional, Assmann, Jorn L.J.C., additional, van der Straten, Lina, additional, Boiten, Henk Jan, additional, Gussinklo, Kirsten J., additional, Valk, Peter J.M., additional, Faber, Laura M., additional, Westerweel, Peter E., additional, Kater, Arnon P., additional, Levin, Mark-David, additional, and Langerak, Anton W., additional

Published
2023
Full Text
View/download PDF

44. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel

Author

Ravandi, Farhad, primary, Cloos, Jacqueline, additional, Buccisano, Francesco, additional, Dillon, Richard, additional, Döhner, Konstanze, additional, Freeman, Sylvie D., additional, Hourigan, Christopher S., additional, Ossenkoppele, Gerrit J., additional, Roboz, Gail J., additional, Subklewe, Marion, additional, Thiede, Christian, additional, Arnhardt, Isabell, additional, Valk, Peter J. M., additional, Venditti, Adriano, additional, Wei, Andrew H., additional, Walter, Roland B., additional, and Heuser, Michael, additional

Published
2023
Full Text
View/download PDF

47. Prospective validation of the prognostic relevance of CD34+CD38– AML stem cell frequency in the HOVON-SAKK132 trial

Author

Ngai, Lok Lam, Hanekamp, Diana, Janssen, Fleur, Carbaat-Ham, Jannemieke, Hofland, Maaike A M, Fayed, Mona M H E, Kelder, Angèle, Oudshoorn-van Marsbergen, Laura, Scholten, Willemijn J, Snel, Alexander N, Bachas, Costa, Tettero, Jesse M, Breems, Dimitri A, Fischer, Thomas, Gjertsen, Bjorn T, Griskevicius, Laimonas, Juliusson, Gunnar, van de Loosdrecht, Arjan A, Maertens, Johan A, Manz, Markus G, Pabst, Thomas, Passweg, Jakob R, Porkka, Kimmo, Valk, Peter J M, Gradowska, Patrycja, Löwenberg, Bob, de Leeuw, David C, Janssen, Jeroen J W M, Ossenkoppele, Gert J, Cloos, Jacqueline, Hematology laboratory, VU University medical center, Hematology, AII - Cancer immunology, AII - Inflammatory diseases, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, and CCA - Cancer Treatment and quality of life

Subjects
All institutes and research themes of the Radboud University Medical Center, Immunology, Cell Biology, Hematology, 610 Medicine & health, Biochemistry, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9]
Abstract

Item does not contain fulltext

Published
2023

48. MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Author

Sanders, Mathijs A., Chew, Edward, Flensburg, Christoffer, Zeilemaker, Annelieke, Miller, Sarah E., al Hinai, Adil S., Bajel, Ashish, Luiken, Bram, Rijken, Melissa, Mclennan, Tamara, Hoogenboezem, Remco M., Kavelaars, François G., Fröhling, Stefan, Blewitt, Marnie E., Bindels, Eric M., Alexander, Warren S., Löwenberg, Bob, Roberts, Andrew W., Valk, Peter J.M., and Majewski, Ian J.

Published
2018
Full Text
View/download PDF

49. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

Author

Zeijlemaker, Wendelien, Grob, Tim, Meijer, Rosa, Hanekamp, Diana, Kelder, Angèle, Carbaat-Ham, Jannemieke C., Oussoren-Brockhoff, Yvonne J. M., Snel, Alexander N., Veldhuizen, Dennis, Scholten, Willemijn J., Maertens, Johan, Breems, Dimitri A., Pabst, Thomas, Manz, Markus G., van der Velden, Vincent H. J., Slomp, Jennichjen, Preijers, Frank, Cloos, Jacqueline, van de Loosdrecht, Arjan A., Löwenberg, Bob, Valk, Peter J. M., Jongen-Lavrencic, Mojca, Ossenkoppele, Gert J., and Schuurhuis, Gerrit J.

Published
2019
Full Text
View/download PDF

50. P318: LOSS OF SCARNA12 RESULTS IN ABERRANT SPLICING OF TARGET GENES AND DOWNREGULATION OF P53 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)

Author

Verbeek, Martijn, primary, Sanders, Mathijs, additional, Grashof, Dwin, additional, van de Werken, Harmen, additional, Van Zuijen, Iris, additional, Bos, Annemarieke, additional, Bindels, Eric, additional, Hoogenboezem, Remco, additional, Valk, Peter, additional, van der Velden, Vincent, additional, and Erkeland, Stefan, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results